Fig. 7.

Rh2 synergizes with recombinant Ad by enhancing the expression of DR4 and DR5, and by inhibiting the expression of FLIP. a THP-1 cells were treated with 0.1 μM sTRAIL for 16 h, 25 μM Rh2 for 4 h, or 25 μM Rh2 for 4 h, followed by 16 h of treatment with 0.1 μM sTRAIL. Cell viability was analyzed using the MTT assay. b IC₅₀ and CI values resulting from the combined effects of Rh2 and sTRAIL in the THP-1 cell line. c THP-1 cells were incubated with/without 25 μM Rh2 for 4 h and then incubated with medium with/without 0.1 μM sTRAIL for 16 h. The expression of PARP and caspase-3 was detected by western blotting with the indicated antibodies. d THP-1 cells were treated with different concentrations of Rh2 for 6 h. Western blot analysis was performed with anti-DR4, anti-DR5, and anti-FLIP antibodies. e THP-1 cells were infected with the three recombinant Ads at an MOI of 150 for 24 h. Cell viability was analyzed using the MTT assay. f, g AML primary cells were treated with 25 μM Rh2 for 4 h and then infected with recombinant Ad at an MOI of 50 for 72 h. The results for all specimens (f) and specimen No. 3 (g) are presented. h AML cells were incubated with/without 25 μM Rh2 for 4 h and protein expression levels were detected using flow cytometry. Three parallel experiments were conducted. Error bars represent the SEM. *P < 0.05; **P < 0.01; ***P < 0.001